Chemical screen identifies PRMT5 as therapeutic goal for paclitaxel-resistant triple-negative breast cancerThese include peer-reviewed journals, government entities and academic establishments, and leaders in dependancy healthcare and advocacy. Find out more regarding how we safeguard our content material by viewing our editorial policy.These cooki